Arbutus, Genevant reject Moderna’s vaccine patent defence

Moderna’s bid to avoid a COVID-19 patent claim has been rejected by two pharma companies that are suing the vaccine manufacturer for infringing its drug delivery technology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Moderna aims to offset COVID vaccine lawsuit to US govt

10 May 2022 Moderna has rejected claims that its COVID-19 vaccine violates the patent rights of two biopharma companies, arguing that its contract with the US federal government has conferred immunity.

Big Pharma

Arbutus, Genevant sue Moderna over COVID-19 vaccine tech

1 March 2022 Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Arbutus, Genevant reject Moderna’s vaccine patent defence

More on this story

Editor's picks

Editor's picks

More features